Metronomic decitabine with venetoclax offers a patient-centered frontline therapeutic approach for TP53-mutated complex-karyotype myeloid neoplasms.
Not available.
We have 2 of 15 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Not available.
This study instigated a gene-specific targeted strategy by unlocking the regulatory network, and designed antisense oligonucleotides (ASOs) targeting important regulatory sites, demonstrating that ASO pharmacology is an actionable strategy for clinical development, challenging the existing paradigms in SF-mutated cance...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.